NeoGenomics, Inc. (NG9)
Munich
Closed
Oct 9, 2026
Day's Range
14.4052 wk Range
6.30Overview - NG9 - NeoGenomics, Inc.
Key Statistics
Valuation
Enterprise Value
249.83M
P/E (Trailing)
‪-20.24‬
PEG Ratio
‪0.19‬
Price / Book
‪2.80‬
EV / EBITDA
‪-22.84‬
Profitability
Gross Margin
‪45.56%‬
Profit Margin
‪43.21%‬
Operating Margin
‪-14.64%‬
Return on Assets
‪-7.94%‬
Return on Equity
‪-12.91%‬
Ownership
Shares Outstanding
127.91M
Price stats
50-Day Avg
‪14.41‬
200-Day Avg
‪10.39‬
Peers - NG9 - NeoGenomics, Inc.
Peer Comparison
Compared with companies in Diagnostics & Research listed on Munich.
- NG9MunichNeoGenomics, Inc.+60.31%52-week change-20.24P/E (Trailing)‪43.21%‬Profit Margin
- 1HMMunichAdaptive Biotechnologies Corporation Common Stock+56.59%52-week change-65.74P/E (Trailing)‪-20.72%‬Profit Margin
- 0MEMunichTwist Bioscience Corporation+85.89%52-week change-126.15P/E (Trailing)‪50.72%‬Profit Margin
- 1K9MunichCareDx, Inc.+75.91%52-week change-133.75P/E (Trailing)‪67.55%‬Profit Margin
- 5GHMunichGuardant Health Inc.+66.74%52-week change-46.63P/E (Trailing)‪64.46%‬Profit Margin
- ILUMunichIllumina Inc.+66.13%52-week change42.93P/E (Trailing)‪66.08%‬Profit Margin
- 04XMunichPersonalis Inc.+64.96%52-week change-15.92P/E (Trailing)‪22.65%‬Profit Margin
Profile Summary - NG9 - NeoGenomics, Inc.
About
NeoGenomics, Inc. is a cancer diagnostics company focused on oncology testing and information services. The company provides a broad menu of laboratory solutions across the cancer care continuum, including molecular testing, next-generation sequencing, fluorescence in situ hybridization, flow cytometry,…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
